Hamps Bio IPO

Incorporated in 2007, Hamps Bio Limited is engaged in the marketing and distribution of pharmaceutical products like tablets, syrups, capsules, injectables, oil, and nutritional supplements. The company distributes its products through a network of over 50 distributors and e-commerce platforms, including Amazon (US, Canada, EU), Flipkart, and Jio Mart. Their pharma products are sold in 8 states and union territories, while Freeze-dried and Frozen products reach 6 countries and 22 states and union territories. The company's business is divided into two segments: Pharmaceuticals: The company's pharmaceutical products are marketed under the "Hamps" brand. The range includes tablets, syrups, capsules, injectables, and powders. Freeze-dried and Frozen products: The FMCG division focuses on freeze-dried and frozen items under the "FzyEzy" brand. The company operates through both B2B and B2C models, offering products under its brand and through contract manufacturing. Freeze-dried and frozen products include Strawberry, Jamun, Mango, Beet Powder, Chikoo powder etc. The company offers over 180 products across both segments. As of October 31, 2024, The company had 78 employees. Competitive Strengths: Expert Leadership and Industry Experience Driving Strategic Business Growth Distribution Network with an Expansive E-Retailing Presence Wide and diversified range of products Diversified, global customer base with long-standing relationships Wide Geographical Presence Brand Identity

The Company intends to use its proceeds as follows: Purchase of plant & machinery for FMCG division Enhancing the visibility and awareness of the brand General corporate purposes

All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions. We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on Information published on this application. No financial information whatsoever published anywhere, within this application, should be considered as advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever Please read all Tearms and conditions , and agree to use the App